Cargando…
Levodopa–carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry
AIM: To evaluate long-term effects of levodopa–carbidopa intestinal gel on dyskinesia burden. PATIENTS & METHODS: Posthoc analysis of the GLORIA registry assessed subgroups of advanced Parkinson's disease patients with <4 and ≥4 h/day of levodopa-induced dyskinesia at baseline. RESULTS &...
Autores principales: | Poewe, Werner, Chaudhuri, K Ray, Bergmann, Lars, Antonini, Angelo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360350/ https://www.ncbi.nlm.nih.gov/pubmed/30547712 http://dx.doi.org/10.2217/nmt-2018-0034 |
Ejemplares similares
-
Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
por: Poewe, Werner, et al.
Publicado: (2019) -
Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2020) -
Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
por: Antonini, Angelo, et al.
Publicado: (2016) -
Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020) -
Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel
por: Ray Chaudhuri, K., et al.
Publicado: (2018)